Recent news on Actimmune

InterMune 1Q Profit Falls on Actimmune  -  May 3, 2007
Forbes,Biotechnology company InterMune Inc. said Thursday its first-quarter loss widened as Actimmune sales fell and costs increased.

InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in ...  -  Apr 6, 2007
Drug Newswire (press release),Based on a preliminary review of the interim safety data, the adverse events associated with Actimmune(R) therapy appear generally consistent with prior

InterMune Updates Expense Forecasts and Development Plans  -  Apr 6, 2007
Drug Newswire (press release),..."We have quickly and aggressively moved to reduce our operating expenses in light of the termination of the INSPIRE trial of Actimmune in IPF," said Dan

Early Termination for Actimmune Study  -  Mar 13, 2007
Facts and Comparisons,An interim analysis demonstrated that IPF patients receiving Actimmune did not benefit from the drug. The trial compared survival data between patients

InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in ...  -  Mar 6, 2007
PharmaLive.com (press release),Based on a preliminary review of the interim safety data, the adverse events associated with Actimmune(R) therapy appear generally consistent with prior

Biotech In Review: InterMune Retrenches  -  Mar 22, 2007
Seeking Alpha,Centient Biotech Investor submits: InterMune (ITMN) scaled back its operations, two weeks after Actimmune failed a Phase III test for idiopathic pulmonary

UPDATE 1-InterMune scraps Actimmune trial for lung disease  -  Mar 5, 2007
ReutersO: Quote, Profile, Research) said it discontinued the late-stage trial of its immune system booster Actimmune in patients with idiopathic pulmonary fibrosis

InterMune Stops Actimmune Trial  -  Mar 5, 2007
Forbes,InterMune Inc., a biotechnology company, said Monday that it has discontinued the clinical trial evaluating the effectiveness of its drug Actimmune in

Patients, Doctors Taken In By Off-Label "Buzz"  -  Mar 20, 2007
Consumer AffairsFor years, desperate pulmonary fibrosis patients -- including World Trade Center rescue workers -- have poured money into a drug called Actimmune,

InterMune Updates Expense Forecasts and Development Plans  -  Mar 20, 2007
Genetic Engineering News (press release),..."We have quickly and aggressively moved to reduce our operating expenses in light of the termination of the INSPIRE trial of Actimmune in IPF," said Dan

InterMune scraps Actimmune trial for lung disease  -  Mar 6, 2007
Therapeutics Daily (subscription) (press release),BANGALORE (Reuters) - InterMune Inc. said it discontinued the late-stage trial of its immune system booster Actimmune in patients with idiopathic pulmonary

InterMune Stopping Phase III IPF Program With Actimmune  -  Mar 6, 2007
Therapeutics Daily (subscription) (press release),Off-label sales of InterMune Inc.?s Actimmune for idiopathic pulmonary fibrosis likely will take a hit from the stoppage of Phase III trials,

InterMune Ends Actimmune Study  -  Mar 5, 2007
TheStreet.comInterMune (ITMN - Cramer's Take - Stockpickr) plunged 12% late Monday after the biotech said it discontinued a late-stage trial of its Actimmune drug for

InterMune to Lay Off Half Its Work Force  -  Mar 20, 2007
Houston Chronicle,The company forecasts first-quarter revenue of about $19 million to $21 million from its drug Actimmune, and about $13 million in collaboration payments

InterMune to lay off half its work force  -  Mar 20, 2007
BusinessWeekThe company forecasts 2007 revenue of about $19 million to $21 million from its drug Actimmune, and about $13 million in collaboration payments from Swiss

Analysts Reaffirm Intermune Ratings  -  Mar 20, 2007
Houston Chronicle,Intermune agreed to pay $37 million in October to settle charges it promoted Actimmune off-label to treat the lung condition, idiopathic pulmonary fibrosis.

InterMune cuts costs: workforce slashed 50%  -  Mar 23, 2007
Therapeutics Daily (subscription) (press release),...trial of Actimunne [interferon gamma 1b] in idiopathic pulmonary fibrosis." This month, InterMune stopped the Phase III study after Actimmune failed

Pitt Center Seeks Patients for Study of Diagnostic and Predictive ...  -  Mar 23, 2007
WebWire (press release),The recent failure of the drug Actimmune as a treatment for idiopathic pulmonary fibrosis (IPF) in a late-stage clinical trial has highlighted the need for

InterMune Reducing Roster By Half To Finance Pipeline  -  Mar 20, 2007
BioWorld Online,In the wake of the Phase III Actimmune fizzle against idiopathic pulmonary fibrosis (IPF) about two weeks ago, InterMune Inc.'s plan to get rid of half its

InterMune to halve work force, cut costs up to $50M  -  Mar 20, 2007
San Jose Business Journal (Subscription),..."We have quickly and aggressively moved to reduce our operating expenses in light of the termination of the Inspire trial of Actimmune in IPF," said Dan

InterMune Slims Down  -  Mar 21, 2007
Motley FoolYesterday, InterMune updated the status of its business and clinical development strategies after its only marketed drug, Actimmune, failed in an important

InterMune Slashing Staffing  -  Mar 20, 2007
TheStreet.comThe move comes just two weeks after InterMune was forced to end a late-stage trial of its Actimmune drug for idiopathic pulmonary fibrosis after the drug

InterMune Report Expense Forecasts And Development Plans; Updates ...  -  Mar 20, 2007
Trading Markets,Looking forward, for the first quarter of 2007, the company expects Actimmune revenues to be in a range of nearly $19 to $21 million.

InterMune to lay off half its staff  -  Mar 21, 2007
Contra Costa Times,On March 5, the company halted a development program called Inspire that was in a Phase III clinical trial of its drug Actimmune targeted at patients with a

Drug Maker Stops Work on Lung Disease Medicine  -  Mar 6, 2007
New York Times,The drug’s maker, InterMune, said yesterday that it was abandoning efforts to develop the product, Actimmune, as a treatment for idiopathic pulmonary

Drug Maker Stops Work on Lung Disease Medicine  -  Mar 5, 2007
New York Times,The drug’s manufacturer, InterMune, said yesterday that it was abandoning efforts to develop the product, Actimmune, as a treatment for idiopathic pulmonary

InterMune Swoons  -  Mar 6, 2007
Motley FoolYesterday, drugmaker InterMune (Nasdaq: ITMN) announced that it was discontinuing development of its lead drug Actimmune as a treatment for a rare lung

Intermune stock battered after IPF trial is halted  -  Mar 7, 2007
Pharma Times (subscription),The news that the USA's InterMune is to halt development of Actimmune in patients with idiopathic pulmonary fibrosis has done major damage to the company's

InterMune Down As Company Halts Trials  -  Mar 6, 2007
Forbes,InterMune Inc. stock fell Tuesday after the company stopped trials for its drug Actimmune, a move analysts say will hurt earnings in the future,

InterMune Down As Company Halts Trials  -  Mar 6, 2007
Houston Chronicle,NEW YORK — InterMune Inc. stock fell Tuesday after the company stopped trials for its drug Actimmune, a move analysts say will hurt earnings in the future,

InterMune (ITMN) Updates Expense Forecasts and Development Plans  -  Mar 20, 2007
StreetInsider.com (subscription),...clinical and regulatory costs due to the termination of the INSPIRE trial; and 3) a reduction of SG&A expenses related to Actimmune.

InterMune Down As Company Halts Trials  -  Mar 6, 2007
MSN MoneyNEW YORK (AP) - InterMune Inc. stock fell Tuesday after the company stopped trials for its drug Actimmune, a move analysts say will hurt earnings in the

Market Report -- In Play (ITMN)  -  Mar 5, 2007
MSN MoneyInterMune discontinues Phase 3 INSPIRE trial of Actimmune in Idiopathic Pulmonary Fibrosis Co announces it has discontinued the Phase 3 INSPIRE clinical

Novartis Up After Drug Approval  -  Mar 6, 2007
Forbes,...based company said it halted clinical trials for its Actimmune drug. While Actimmune is already approved for the treatment of two other diseases,

Ahead of the Bell: InterMune  -  Mar 6, 2007
Houston Chronicle,NEW YORK — Analysts responded Tuesday to biotechnology company InterMune Inc.'s announcement that it will stop testing its drug Actimmune in patients with

Ahead of the Bell: InterMune  -  Mar 6, 2007
Forbes,Analysts responded Tuesday to biotechnology company InterMune Inc.'s announcement that it will stop testing its drug Actimmune in patients with the lung

Ahead of the Bell: InterMune  -  Mar 6, 2007
MSN MoneyNEW YORK (AP) - Analysts responded Tuesday to biotechnology company InterMune Inc.'s announcement that it will stop testing its drug Actimmune in patients

InterMune Plummets After Halting Key Trial  -  Mar 7, 2007
MSNBCThe trials were for the drug Actimmune, a human protein designed to trigger an immune system response in patients. InterMune markets the drug to halt the

Stocks in the Spotlight Tuesday  -  Mar 6, 2007
Barron's (subscription)Shares fell 21% after InterMune discontinued trials for Actimmune, a lung-disease treatment. The company said that there was not a statistically significant

InterMune shares plunge on poor trial results  -  Mar 6, 2007
MarketWatch...said that an independent committee monitoring a Phase III clinical trial of Actimmune recommended the study be halted after interim analysis showed the drug

InterMune extends filing date for annual report  -  Mar 16, 2007
Therapeutics Daily (subscription) (press release),It needs more time to review certain additional disclosures and financial implications of its decision to discontinue phase 3 trial of Actimmune for the

InterMune Extends Filing Date for Annual Report  -  Mar 15, 2007
Reuters.uk,It needs more time to review certain additional disclosures and financial implications of its decision to discontinue Phase 3 trial of Actimmune for the

InterMune wants filing extension  -  Mar 15, 2007
BusinessWeekLast week Intermune discontinued a clinical trial evaluating the effectiveness of its drug Actimmune in patients with idiopathic pulmonary fibrosis,

InterMune Announces Fourth Quarter and Full Year 2006 Financial ...  -  Feb 9, 2007
PharmaLive.com (press release),Total product revenue for the fourth quarter of 2006 was $19.4 million, comprised solely of Actimmune(R) (interferon gamma-1b) revenue, compared to $29.0

UPATE 1-InterMune posts 4th-quarter loss, shares fall  -  Feb 8, 2007
ReutersO: Quote, Profile , Research) reported a fourth-quarter loss on Thursday on declining sales of its lone marketed product, Actimmune, and it forecast 2007

Here Comes the Boom for InterMune  -  Feb 12, 2007
Motley FoolPhase 3 results from Actimmune are expected in January of 2008, and its other IPF program -- which caused shares to jump in December -- will complete phase

Intermune Swings to 4Q Loss  -  Feb 8, 2007
Forbes,Its Actimmune product accounted for virtually all product revenue and was down 31 percent from $28.2 million a year ago. The company generated no revenue

InterMune posts 4th-quarter loss  -  Feb 8, 2007
ReutersO: Quote, Profile , Research) reported a fourth-quarter loss on Thursday as results were hit by declining sales of its lone marketed product, Actimmune,

InterMune to Present at the SIGnificant Investment Options in ...  -  Feb 23, 2007
PR Newswire (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

US Attorney Kevin V. Ryan Announces Departure - Northern District ...  -  Feb 15, 2007
Lawfuel (press release),...criminal charges and civil liability in connection with its illegal promotion and marketing of its drug Actimmune (Interferon gamma-1b) in October 2006.

InterMune's Secret Drug Surprise  -  Dec 26, 2006
Motley FoolInterMune is also testing its already approved drug, named Actimmune, in treating idiopathic pulmonary fibrosis, or IPF. Results of a large phase 3 trial

InterMune "buy"  -  Dec 27, 2006
newratings.comInterMune’s pipeline includes two other viable products, namely Actimmune and ITMN-191, the analysts say. Rising visibility into ITMN-191 for HCV and an

UPDATE 1-InterMune shares up 29 pct on Japan lung data  -  Dec 22, 2006
ReutersPirfenidone could be viewed as a third viable product in Intermune's pipeline, which includes immune-booster Actimmune and ITMN-191, which is being

InterMune Achieves Manufacturing Milestone in HCV Collaboration ...  -  Jan 9, 2007
PharmaLive.com (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

InterMune's Secret Drug Surprise  -  26 Dec 2006
Motley FoolInterMune is also testing its already approved drug, named Actimmune, in treating idiopathic pulmonary fibrosis, or IPF. Results of a large phase 3 trial

United States: Intermune’s CIA Signals OIG’s Expectations For ...  -  Dec 5, 2006
Mondaq News Alerts (subcription),As set forth in the DPA, although Actimmune was approved by the Food and Drug Administration ("FDA") for the treatment of chronic granulatomous disease and

HIV drug maker receives subpoena  -  Dec 9, 2006
Contra Costa Times,Although the FDA had approved Actimmune for treating a bone disorder and a condition that makes people prone to infections, InterMune was accused of

FOSTER CITY US issues subpoena to HIV drug firm  -  Dec 8, 2006
San Francisco Chronicle,...pay $36.9 million to settle claims by the US attorney's office in San Francisco that it illegally marketed its drug Actimmune for a fatal lung disorder.

InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C ...  -  Dec 20, 2006
Drug Newswire (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

Aerovance Adds Accomplished Product Commercialization Executive to ...  -  Dec 18, 2006
Drug Newswire (press release),Happel was the senior director for Intermune, Inc.'s pulmonary business unit, where he launched the company's US commercial initiatives for Actimmune(R)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional